Review Soybeans as bioreactors for biopharmaceuticals and industrial proteins

Vianna, Giovanni R.; Cunha, Nicolau Brito da; Murad, André M.; Rech, E. L.

doi:10.4238/vol10-3gmr1476

Cited by 24 publications

(33 citation statements)

References 52 publications

(105 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The answer to this question is simple; biotechnology is helpful in this regard. Crops can be used as bioreactors and after this they can produce lots of molecules of different combinations [16][17][18][19]. We can say that a transgenic plant is used as a vehicle to express characters which are injected into them by carriers in the form of proteins commonly known as antigens.…”

Section: A Rt I C L E I N F O Abstractmentioning

confidence: 99%

See 1 more Smart Citation

Biotechnological leap in biopharmaceuticals: Current status and challenges ahead

2016

J Coast Life Med

View full text Add to dashboard Cite

Section: A Rt I C L E I N F O Abstractmentioning

confidence: 99%

“…Thus the plants are able to serve as a booster preparation tool [22]. The use of antitoxins of plant origin is very useful in areas where we cannot maintain cold chain system [17][18][19]23]. For the previous 10 years, the researchers have invented a large amount of vaccinations of plant origin.…”

Section: A Rt I C L E I N F O Abstractmentioning

confidence: 99%

Biotechnological leap in biopharmaceuticals: Current status and challenges ahead

2016

J Coast Life Med

View full text Add to dashboard Cite

“…Transgenic plant have been found to have many advantages like, development of high yielding varieties of crop plants and disease resistant, and are plants with improved tolerance to biotic and abiotic stress (Ahmad et al, 2008;2010a;Ahmad and Prasad, 2012a;Sarwat et al, 2012). Apart from the above, transgenic plants have been employed for the production of vaccines for the treatment of various infectious diseases (Kant et al, 2011;Vianna et al, 2011;Yoshida et al, 2011;Sharma and Sood, 2011;Twyman et al, 2012). Infectious diseases are major cause of mortality and morbidity worldwide (Goldblatt and Ramsay, 2003) and one-third of the deaths are caused by the infectious agents.…”

Section: Introductionmentioning

confidence: 99%

“…Now the question arises what is plant derived vaccine? Advances in transgenic research have made use of crop plants to serve as bioreactor for the production of recombinant molecules (Raskin et al, 2002;Kant et al, 2011;Vianna et al, 2011;Yoshida et al, 2011;Sharma and Sood, 2011). This means that transgenic plants are used to express antigen proteins induced by plant transgenic vectors and to produce certain special vaccines with high anti-disease ability (reviewed by Mei et al, 2006;Malabadi et al, 2012) (Figure 1).…”

Section: Introductionmentioning

confidence: 99%

“…This means that transgenic plants are used to express antigen proteins induced by plant transgenic vectors and to produce certain special vaccines with high anti-disease ability (reviewed by Mei et al, 2006;Malabadi et al, 2012) (Figure 1). Plant derived vaccines significantly increase availability of vaccines in places where maintenance of cold chain system is difficult (Webster et al, 2002;Kant et al, 2011;Vianna et al, 2011;Yoshida et al, 2011;Sharma and Sood, 2011;Twyman et al, 2012). Important examples on the development of plant bioreactors are shown in Table 1.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Transgenic plants as green factories for vaccine production

Kumar¹,

Raja²,

Wani³

et al. 2013

Afr. J. Biotechnol.

View full text Add to dashboard Cite

Edible vaccine technology represents an alternative to fermentation based vaccine production system. Transgenic plants are used for the production of plant derived specific vaccines with native immunogenic properties stimulating both humoral and mucosal immune responses. Keeping in view the practical need of new technology for production and delivery of inexpensive vaccines, especially in developing world, plant derived edible vaccines is the best option in hand to combat infectious diseases. Plant derived vaccine is easy to administer, cost effective, readily acceptable, have increased safety, stability, versatility and efficacy. Several plant derived vaccines are under research, some are under clinical trials for commercial use. Like most biotechnology products, the IP situation for edible vaccines is complex as IP rights influence every stage of vaccine development.

show abstract

Molecular farming of human cytokines and blood products from plants: Challenges in biosynthesis and detection of plant‐produced recombinant proteins

Cunha

Vianna

Lima

et al. 2013

Biotechnology Journal

View full text Add to dashboard Cite

Plants have emerged as an attractive alternative to the traditional mammalian cell cultures or microbial cell-based systems system for the production of valuable recombinant proteins. Through recombinant DNA technology, plants can be engineered to produce large quantities of pharmaceuticals and industrial proteins of high quality at low costs. The recombinant production, by transgenic plants, of therapeutic proteins normally present in human plasma, such as cytokines, coagulation factors, anticoagulants, and immunoglobulins, represents a response to the ongoing challenges in meeting the demand for therapeutic proteins to treat serious inherited or acquired bleeding and immunological diseases. As the clinical utilization of fractionated plasma molecules is limited by high production costs, using recombinant biopharmaceuticals derived from plants represents a feasible alternative to provide efficient treatment. Plant-derived pharmaceuticals also reduce the potential risks to patients of infection with pathogens or unwanted immune responses due to immunogenic antigens. In this review, we summarize the recent advances in molecular farming of cytokines. We also examine the technological basis, upcoming challenges, and perspectives for the biosynthesis and detection of these molecules in different plant production platforms.

show abstract

Review Soybeans as bioreactors for biopharmaceuticals and industrial proteins

Cited by 24 publications

References 52 publications

Biotechnological leap in biopharmaceuticals: Current status and challenges ahead

Biotechnological leap in biopharmaceuticals: Current status and challenges ahead

Transgenic plants as green factories for vaccine production

Molecular farming of human cytokines and blood products from plants: Challenges in biosynthesis and detection of plant‐produced recombinant proteins

Contact Info

Product

Resources

About